Tag Archive for: STEAP1

QLS2401: A Trispecific PSMA/STEAP1/CD3 T‑Cell Engager for mCRPC

QLS2401 is a trispecific T‑cell engager designed for metastatic castration‑resistant prostate cancer (mCRPC). It binds three targets at once: PSMA and STEAP1 on tumor cells, plus CD3 on T cells. This design allows it to physically connect a patient’s T cells to prostate‑cancer cells, triggering T‑cell activation and killing of the tumor. Both PSMA and […]

HLX3902: A Trispecific T‑Cell Engager Rewiring the Immune Desert in Prostate Cancer

HLX3902 is a STEAP1×CD3×CD28 trispecific T‑cell engager developed as a potential first‑in‑class immunotherapy for prostate cancer. Prostate tumors are largely “cold” from an immunological standpoint. The microenvironment is immunosuppressive, T cells are scarce inside the tumor mass, and those that do infiltrate often burn out quickly after activation. Classical CD3‑only bispecific TCEs can force T […]

Phase 1 Trial: STEAP1 CAR‑T Plus Enzalutamide A New Immune Approach for mCRPC

STEAP1 is a protein that sits on the surface of many prostate cancer cells, especially in advanced metastatic disease. Because it is abundant on cancer cells and much less present in normal tissues, STEAP1 looks like a promising “flag” that engineered immune cells can use to distinguish tumor from healthy organs. ​ The treatment being […]

Phase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer